Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN-B00009 in type 2 diabetes inadequately controlled by diet and exercise
NCT07308184Phase 3Not yet recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Peptides
01
Overview
A Phase 3 trial of ecnoglutide in type 2 diabetes mellitus (T2DM), sponsored by HK inno.N Corporation. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07308184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308184.